The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...
High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.
Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...
identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as do other candidates in the late-stage ...
The FDA said on its website: “FDA has required and approved safety labeling changes to the prescribing information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
"Human Respiratory Syncytial Virus" [Micrograph ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year in the fourth quarter. The company attributed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback